CytoImmune Therapeutics welcomes Graeme Bell to its Board of Directors

– USA, CA –  CytoImmune Therapeutics, a clinical-stage immuno-oncology company, today announced the appointment of Graeme Bell to its Board of Directors.

“We’re pleased to welcome Graeme to our Board as we seek to develop our pipeline of products for multiple solid tumor indications. Not only does Graeme have a deep background in oncology and cell therapy, he also has a keen knowledge of the pharmaceutical business and financial landscape. I look forward to partnering with both Yulii and Graeme during this exciting time at CytoImmune.” said CEO, Dr. Christina Coughlin.

Concurrently, Yulii Bogatyrenko has been appointed as CBO, bringing over 20 years of experience leading business and commercial functions at successful organizations within the biopharmaceutical industry.

About Graeme Bell

Graeme Bell is a distinguished financial executive who brings 30 years of experience in the biopharmaceutical sector. Before Valo, he was CFO at Tmunity Therapeutics, and earlier, CFO at Intellia Therapeutics, where he helped scale the newly public company, overseeing strategic operational financial functions, investor relations, IT, and strategic planning. Mr. Bell was also CFO at Anacor Pharmaceuticals, which was acquired by Pfizer. In addition, he spent over 20 years at Merck & Co, Inc. gaining extensive experience in finance and business leadership roles, including as CFO of U.S. operations and global head of investor relations.

About CytoImmune

CytoImmune Therapeutics is a clinical-stage immune-oncology company focused on the development and commercialization of novel cancer immunotherapy products that empower the engineered effector cells to activate the patient’s immune system against cancer cells.

The company has a focus on solid tumors and is leveraging our engineered cord blood NK cells as the therapy backbone. The company’s pipeline includes the tumor-reactive NK cell platform of assets in combination with engager and monoclonal antibody therapies that target gastric, pancreatic, non-small cell lung, ovarian, and endometrial indications, among others.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.